CAS: 15872-43-2; 4-(Nonyloxy)Benzoic Acid

相似化合物

50262-46-9 15872-42-1 2312-15-4

上下游产品

CAS号693-58-3 1-溴壬烷 | CAS号99-96-7 4-羟基苯甲酸 | CAS号147080-44-2 METHYL 4-N-NONY... | CAS号99-76-3 尼泊金甲酯 | CAS号120-47-8 尼泊金乙酯 | CAS号143-08-8 1-壬醇 | CAS号2473-01-0 1-氯壬烷 | CAS号16782-08-4 四羟基苯甲酸一钾 | CAS号4282-42-2 1-碘壬烷 | CAS号70280-78-3 (4-butylphenyl)... | CAS号56800-34-1 (4-formylphenyl... | CAS号55768-36-0 4-nonoxybenzoyl...

📜1-溴壬烷置于水,Potassium Carbonate,溶剂黄146,Potassium Hydroxide体系中,用 乙醇 用作溶剂,化学反应生成4-壬氧基苯甲酸
参考文献:具有二烷基氨基末端取代基的新型席夫碱酯的合成与介晶作用
标题:具有二烷基氨基末端取代基的新型席夫碱酯的合成与介晶作用
摘要:报道了含有由三个苯环组成的介晶核心体系的新型棒状液晶,4-[{[4-(二乙氨基)苯基]亚甲基}氨基]苯基4-烷氧基苯甲酸酯(Neabaa).酯键和亚胺键连接苯环.在分子的一端,核心系统连接到具有可变长度-(Ch2)N-的烷氧基链(其中n = 2-10,12,14,16和18).在分子的另一端,苯环的对位与二乙氨基键合.通过光谱方法确认了当前化合物的分子结构.通过使用差示扫描量热计和连接到加热台的偏光光学显微镜研究了标题化合物的介晶特征.通过显微镜观察,发现所有合成的化合物仅表现出单一(向列)相.当前化合物中表现出的单相变化(向列)是由连接到亚苄基苯胺核心系统末端位置的二乙氨基的存在引起的.二乙氨基导致分子宽度增加,这导致整体横向分子间吸引力较弱.随后,它降低了化合物的中间相热稳定性.将当前化合物的热性能与先前报道的类似物进行比较,并通过这种比较推断出当前化合物的结构-性能关系.
Doi:10.2174/0115701786295452240327060732

专利信息

专利号:US-9217012-B2
优先权日:2009-04-08
标题 :Inhibitors of protein tyrosine phosphatases
发明人：ZHANG ZHONG-YIN; ZHANG SHENG
权利人:ZHANG ZHONG-YIN; ZHANG SHENG; UNIV INDIANA RES & TECH CORP
摘要:Disclosed herein are compounds that selectively inhibit members of the PTP family of enzymes. Synthesized compounds demonstrated selective inhibition of TC-PTP. Also provided are methods of using the compounds and formulations containing the compounds. Also described is a fluorescence-tagged combinatorial library synthesis and screening method. And methods of using these compounds to effect enzyme activity both in cells and in vitro as well as method of using these compounds to treat diseases in human and animals.

专利号:US-9700543-B2
优先权日:2011-05-31
标题 :GLP-1 receptor stabilizers and modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; BRAHMACHARY ENUGURTHI; YEAGER ADAM RICHARD
权利人:CELGENE INT II SÀRL
摘要:Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP(1-42), PTH(1-34), Glucagon(1-29), GLP-2(1-33), GLP-1(7-36), GLP-1(9-36), oxyntomodulin and exendin variants.